ADHD Therapeutics Market Size and Share|2030

ADHD Therapeutics Market Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Drug Type (Stimulants and Non-Stimulants), Age Group (Pediatric & Adolescent and Adults), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and E-Commerce)

Publication Month : Jan 2024

  • Report Code : TIPRE00003833
  • Category : Pharmaceuticals
  • Status : Data Released
  • No. of Pages : 150
Inquire Before Buy

PRICING

$5190

$4671

[Research Report] The ADHD therapeutics market size was valued at US$ 28,594.55 million in 2022 and is expected to reach US$ 64,742.37 million by 2030; it is estimated to record a CAGR of 10.8% during 2022–2030. 

Market Insights and Analyst View:

Attention deficit/hyperactivity disorder (ADHD) is a complex neurodevelopment disorder that affects individuals’ ability to focus, control impulsive behaviors, and manage hyperactivity. It is mostly diagnosed in childhood, but symptoms can persist into adolescence and adulthood. Treatment for ADHD often involves a multidisciplinary approach, including behavioral therapy, education, and medication such as stimulants and non-stimulants.

Factors such as the growing prevalence of ADHD and a surge in the demand for treatment drugs propel the growth of the market. However, side effects associated with ADHD drugs and their limited relief impede the ADHD therapeutics market growth.

Growth Drivers and Restraints:

As per the article published by the Centers for Disease Control and Prevention (CDC), in February 2022, approximately 6 million children aged 3–17 years in the US were diagnosed with ADHD, accounting for 9.8% of the population between 2016 and 2019. Additionally, according to an article published by PubMed Central in 2022, ADHD affects 5–7.2% of children and 2.5–6.7% of adults worldwide. According to recent estimates, the frequency of adolescents in the US is much greater, at roughly 8.7% or 5.3 million. Although it has traditionally been thought of as a childhood condition, up to 90% of children with ADHD continue to have symptoms in adulthood. It is also possible to diagnose in adults because 75% of individuals with ADHD were not previously diagnosed during childhood, according to a research study. ADHD is frequently associated with comorbid conditions such as anxiety, depression, learning disorders, and substance abuse. The presence of these comorbidities increases the treatment complexity, necessitating a multi-dimensional approach that addresses both ADHD symptoms and associated conditions. Drugs such as psychostimulants and non-stimulants are recommended, which can assist children in managing their ADHD symptoms in their daily lives and can help regulate behaviors that may cause difficulties in various aspects of their lives, including personal life and academic performance. Thus, the factors mentioned above are increasing the demand for drugs indicated for ADHD, facilitating the expansion of the ADHD therapeutics market share.

However, the growth of the ADHD therapeutics market is restricted due to the limited relief of symptoms and the side effects associated with the use of therapeutics. Common side effects of psychostimulant medication include decreased appetite, insomnia, increased anxiety, increased irritability, stomach ache, and headache. When the effects of the medication wear off, ADHD symptoms may return, causing the "rebound" effect that can be more intense.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

ADHD Therapeutics Market: Strategic Insights

adhd-therapeutics-market
Market Size Value inUS$ 28,594.55 million in 2022
Market Size Value byUS$ 64,742.37 million by 2030
Growth rateCAGR of 10.8% from 2022 to 2030
Forecast Period2022-2030
Base Year2022
Analyst Image

Akshay

Have a question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Analyst Image  Speak to Analyst

Report Segmentation and Scope:

The “ADHD therapeutics market analysis” has been carried out by considering the following segments: drug type, age group, and distribution channel.

  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
  • Request discounts available for Start-Ups & Universities

Segmental Analysis:

The ADHD therapeutics market, by drug type, is segmented into stimulants and non-stimulant drugs.

The stimulant drug segment held a larger ADHD therapeutics market share in 2022 and is anticipated to register a higher CAGR during 2022–2030.

ADHD Therapeutics Market by Drug Type – 2022 and 2030

  • Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
  • Request discounts available for Start-Ups & Universities

Based on age group, the ADHD therapeutics market is segmented into pediatric & adolescent and adult. The pediatric & adolescent segment held a larger market share in 2022. The adult segment is anticipated to register a higher CAGR from 2022 to 2030.

In terms of distribution channel, the ADHD therapeutics market is categorized into hospital pharmacies, retail pharmacies, and E-commerce. In 2022, the hospital pharmacies segment held the largest market share and is anticipated to register the highest CAGR during 2022–2030.

Regional Analysis:

North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa are the major regions analyzed for deriving the ADHD therapeutics market report scope.

In 2022, North America held the largest global market share. In North America, the US held the largest share of the market in 2022 and is estimated to continue its dominance from 2022 to 2030. The ADHD therapeutics market growth is largely driven due to the high prevalence of ADHD in the US. According to Cingulate, ~6.4 million children and adolescents between 4 and 17 years of age were diagnosed with ADHD in 2022. Among them, over 80% of this group receive treatment, and about 65% experience ongoing symptoms of ADHD into adulthood. Additionally, improved patient affordability, favorable reimbursement policies, and increased awareness of current drugs are expected to drive market growth.

Asia Pacific is the fastest-growing market for ADHD owing to the presence of key players in the region and several strategic initiatives undertaken to develop and market new products. For example, in June 2020, Otsuka Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Development & Commercialization, Inc. reported positive results from its two six-week phase 3 clinical trials that assessed the effectiveness, safety, and tolerability of oral centanafadine. Centanafadine is a new experimental drug designed to treat adult patients diagnosed with ADHD. The company also planned to study the effects of centanafadine in children with ADHD and to discuss the next steps with the US Food and Drug Administration.

Industry Developments and Future Opportunities:

The ADHD therapeutics market forecast can help stakeholders in this marketplace plan their growth strategies. Initiatives taken by key players performing in the market are listed below:

  1. In September 2023, Cingulate Inc. announced results from its Phase 3 study of adult efficacy and safety of its lead candidate, CTx-1301 (dexmethylphenidate), for treating ADHD. The company utilizes Precision Timed Release (PTR), its patented drug delivery platform technology, to build and advance a pipeline of next-generation pharmaceutical products. The results were presented on September 8th at the 36th Annual Psych Congress in Nashville, TN.
  2. In March 2022, Noven Pharmaceuticals, Inc., a completely owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., got approval from the US Food and Drug Administration (FDA) for its XELSTRYM (dextroamphetamine) transdermal system, CII, for the treatment of ADHD in adults and pediatric patients aged six years and above.
  3. In July 2021, Corium, Inc. launched AZSTARYS. This innovative medication combines Serdexmethylphenidate (SDX) and dexmethylphenidate (d-MPH) in the US for symptomatic treatment in patients aged 6 years and above. AZSTARYS got FDA approval in March 2021. It comprises a combination of two types of medication: 70% extended-release prodrug of d-MPH SDX (Schedule IV) and 30% immediate-release d-MPH (Schedule II).
  4. In April 2021, Supernus Pharmaceuticals, Inc. announced that the US FDA had approved a Qelbree (viloxazine extended-release capsules) to treat ADHD in patients aged 6–17.

Competitive Landscape and Key Companies:

Amneal Pharmaceuticals, Inc.; Novartis AG; Pfizer, Inc.; Eli Lilly and Company; Noven Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Johnson & Johnson Services, Inc.; Corium Inc; Adlon Therapeutics LP; and Teva Pharmaceutical Industries Ltd. are among the key players profiled in the ADHD therapeutics market report. These companies adopt product development strategies to meet growing customer demands, which allows them to maintain their brand name.

Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

Drug Type, Age Group, and Distribution Channel

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


What was the estimated size of the ADHD Therapeutics market in 2022?

The digital health market was valued at US$ 28,594.55 billion in 2022.

Which drug type segment dominates the ADHD Therapeutics market?

The ADHD Therapeutics market, by drug type, is segmented into stimulants and non-stimulant drugs. The stimulant drug segment held a larger market share in 2022, and the same segment is anticipated to register a higher CAGR during 2022-2030.

Which end-user segment dominates the ADHD Therapeutics market?

The ADHD Therapeutics market, by end-user, is segmented into hospitals and clinics, providers, payers, and others. In 2022, the hospitals and clinics segment held the largest market share, and the same segment is anticipated to register the highest CAGR during 2022–2030.

What is ADHD?

Attention deficit/hyperactivity disorder (ADHD) is a complex neurodevelopment disorder that affects individuals’ ability to focus, control impulsive behaviors, and manage hyperactivity. It is mostly diagnosed in childhood, but symptoms can persist into adolescence and adulthood. Treatment for ADHD often involves a multidisciplinary approach, including behavioral therapy, education, and medication such as stimulants and non-stimulants.

Who are the major players in the ADHD Therapeutics market?

The digital health market majorly consists of the players, including Amneal Pharmaceuticals, Inc.; Novartis AG; Pfizer, Inc.; Eli Lilly and Company; Noven Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Johnson & Johnson Services, Inc.; Corium Inc; Adlon Therapeutics LP; and Teva Pharmaceutical Industries Ltd. are among the key players profiled in the ADHD therapeutics market.

What factors drive the ADHD Therapeutics market?

Key factors driving the increasing prevalence of ADHD, combined with the increased demand for drugs for treatment, is propelling the market.

1. Introduction

1.1 Scope of the Study

1.2 Market Definition, Assumptions and Limitations

1.3 Market Segmentation

2. Executive Summary

2.1 Key Insights

2.2 Market Attractiveness Analysis

3. Research Methodology

4. ADHD Therapeutics Market Landscape

4.1 Overview

4.2 PEST Analysis

4.3 Ecosystem Analysis

4.3.1 List of Vendors in the Value Chain

5. ADHD Therapeutics Market - Key Market Dynamics

5.1 Key Market Drivers

5.2 Key Market Restraints

5.3 Key Market Opportunities

5.4 Future Trends

5.5 Impact Analysis of Drivers and Restraints

6. ADHD Therapeutics Market - Global Market Analysis

6.1 ADHD Therapeutics - Global Market Overview

6.2 ADHD Therapeutics - Global Market and Forecast to 2030

7. ADHD Therapeutics Market – Revenue Analysis (USD Million) – By Drug Type, 2020-2030

7.1 Overview

7.2 Stimulants

7.3 Non-Stimulants

8. ADHD Therapeutics Market – Revenue Analysis (USD Million) – By Age Group, 2020-2030

8.1 Overview

8.2 Pediatric and Adolescent

8.3 Adults

9. ADHD Therapeutics Market – Revenue Analysis (USD Million) – By Distribution Channel, 2020-2030

9.1 Overview

9.2 Hospital Pharmacies

9.3 Retail Pharmacies

9.4 E-Commerce

10. ADHD Therapeutics Market - Revenue Analysis (USD Million), 2020-2030 – Geographical Analysis

10.1 North America

10.1.1 North America ADHD Therapeutics Market Overview

10.1.2 North America ADHD Therapeutics Market Revenue and Forecasts to 2030

10.1.3 North America ADHD Therapeutics Market Revenue and Forecasts and Analysis - By Drug Type

10.1.4 North America ADHD Therapeutics Market Revenue and Forecasts and Analysis - By Age Group

10.1.5 North America ADHD Therapeutics Market Revenue and Forecasts and Analysis - By Distribution Channel

10.1.6 North America ADHD Therapeutics Market Revenue and Forecasts and Analysis - By Countries

10.1.6.1 United States ADHD Therapeutics Market

10.1.6.1.1 United States ADHD Therapeutics Market, by Drug Type

10.1.6.1.2 United States ADHD Therapeutics Market, by Age Group

10.1.6.1.3 United States ADHD Therapeutics Market, by Distribution Channel

10.1.6.2 Canada ADHD Therapeutics Market

10.1.6.2.1 Canada ADHD Therapeutics Market, by Drug Type

10.1.6.2.2 Canada ADHD Therapeutics Market, by Age Group

10.1.6.2.3 Canada ADHD Therapeutics Market, by Distribution Channel

10.1.6.3 Mexico ADHD Therapeutics Market

10.1.6.3.1 Mexico ADHD Therapeutics Market, by Drug Type

10.1.6.3.2 Mexico ADHD Therapeutics Market, by Age Group

10.1.6.3.3 Mexico ADHD Therapeutics Market, by Distribution Channel

Note - Similar analysis would be provided for below mentioned regions/countries

10.2 Europe

10.2.1 Germany

10.2.2 France

10.2.3 Italy

10.2.4 Spain

10.2.5 United Kingdom

10.2.6 Rest of Europe

10.3 Asia-Pacific

10.3.1 Australia

10.3.2 China

10.3.3 India

10.3.4 Japan

10.3.5 South Korea

10.3.6 Rest of Asia-Pacific

10.4 Middle East and Africa

10.4.1 South Africa

10.4.2 Saudi Arabia

10.4.3 U.A.E

10.4.4 Rest of Middle East and Africa

10.5 South and Central America

10.5.1 Brazil

10.5.2 Argentina

10.5.3 Rest of South and Central America

11. Industry Landscape

11.1 Mergers and Acquisitions

11.2 Agreements, Collaborations, Joint Ventures

11.3 New Product Launches

11.4 Expansions and Other Strategic Developments

12. Competitive Landscape

12.1 Heat Map Analysis by Key Players

12.2 Company Positioning and Concentration

13. ADHD Therapeutics Market - Key Company Profiles

13.1 Amneal Pharmaceuticals, Inc

13.1.1 Key Facts

13.1.2 Business Description

13.1.3 Products and Services

13.1.4 Financial Overview

13.1.5 SWOT Analysis

13.1.6 Key Developments

Note - Similar information would be provided for below list of companies

13.2 Novartis AG

13.3 Pfizer, Inc.

13.4 Eli Lilly and Company

13.5 Noven Pharmaceuticals, Inc.

13.6 Janssen Pharmaceuticals, Inc

13.7 Johnson and Johnson Services, Inc.

13.8 Corium Inc

13.9 Adlon Therapeutics L.P

13.10 Teva Pharmaceutical Industries Ltd

14. Appendix

14.1 Glossary

14.2 About The Insight Partners

14.3 Market Intelligence Cloud

The List of Companies - ADHD Therapeutics Market

  1. Amneal Pharmaceuticals, Inc
  2. Novartis AG
  3. Pfizer, Inc.
  4. Eli Lilly And Company
  5. Noven Pharmaceuticals, Inc.
  6. Janssen Pharmaceuticals, Inc
  7. Johnson & Johnson Services, Inc.
  8. Corium Inc
  9. Adlon Therapeutics L.P
  10. Teva Pharmaceutical Industries Ltd

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • 3.1 Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • 3.2 Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • 3.3 Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • 3.4 Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Trends and growth analysis reports related to ADHD Therapeutics Market